Ancora Advisors’s Psyence Biomedical Warrant PBMWW Stock Holding History

Ancora Advisors’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$121	Hold	5,000	–	–	﹤0.01%	1945
2026 Q1	$90	Hold	5,000	–	–	﹤0.01%	2354
2025 Q4	$92	Hold	5,000	–	–	﹤0.01%	2389
2025 Q3	$126	Hold	5,000	–	–	﹤0.01%	1918
2025 Q2	$101	Hold	5,000	–	–	﹤0.01%	1917
2025 Q1	$84	Hold	5,000	–	–	﹤0.01%	1727
2024 Q4	$72	Hold	5,000	–	–	﹤0.01%	1773
2024 Q3	$63	Hold	5,000	–	–	﹤0.01%	1749
2024 Q2	$52	Hold	5,000	–	–	﹤0.01%	1802
2024 Q1	$350	Buy	+5,000	New	+$312	﹤0.01%	1704

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ancora Advisors's PBMWW Position: Q2 2026 in Review

Ancora Advisors held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 5,000 shares worth $121. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

Ancora Advisors first reported a position in PBMWW in Q1 2024 and has held it in 10 quarters since. The position peaked at $350 in Q1 2024. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

Ancora Advisors held 5,000 shares of Psyence Biomedical Warrant worth $121 as of Q2 2026.
Ancora Advisors left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1945 holding.
Ancora Advisors first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 10 quarters since.
Ancora Advisors's Psyence Biomedical Warrant position peaked at $350 in Q1 2024.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.